From Spider Silk to Silk Roads: Microcaps Flex Real-World Momentum

August 28, 2025

DENVER, Colo., Aug 28, 2025 (247marketnews.com)- Micro- and small-cap names are making outsized moves, driven by operational milestones, AI pivots, and near-term revenue catalysts.

Kraig Biocraft Laboratories (OTCQB:KBLB) confirmed its second ASEAN production facility is fully operational, just in time to fulfill a specialized order from a global performance textile brand. The company’s BAM-1 hybrid spider silk, renowned for strength, elasticity, and biodegradability, is finally entering scale.

The facility expansion is designed to “prevent past production delays” and support the rollout of new high-performance strains introduced this summer.

With commercial deliveries imminent and more announcements expected in Q4, KBLB is making its long-awaited move from R&D to revenue. Investors are watching closely, as the company aims to become a key player in the multi-billion-dollar technical fibers market.

Pasithea Therapeutics (NASDAQ:KTTA) remains in focus following recent clinical developments around its psychedelic-assisted therapeutic models. While no formal update hit wires today, the stock has seen increased chatter among retail traders amid sector-wide recovery in mental health biotech.

Erayak Power Solution (NASDAQ:RAYA) is an off-grid and backup power equipment maker is holding steady as energy security continues to trend globally. Investors are speculating on further market expansion in Southeast Asia and the Middle East, where the company has existing distribution networks.

Top KingWin (NASDAQ:WAI) extended yesterday’s gains as the company accelerates its AI-driven consulting pivot, specifically targeting Chinese SMEs and executives.

This marks a structural transition away from traditional finance toward digital transformation services, with investors responding positively to early traction.

Invivyd (NASDAQ:IVVD) is seeing growing investor interest following recent leadership hires and progress on its infectious disease pipeline. Still in the early clinical stage, Invivyd is positioning itself as a next-gen biotech disruptor with a unique approach to immune resilience and outbreak readiness.

Analysts have pointed to IVVD’s “strategic platform potential” in designing rapid-response antibody therapies as a competitive edge in post-pandemic biotech.

Please click here to read the full Kraig Labs analyst report on 247marketnews.com.

For more information, please visit: www.kraiglabs.com

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

Please go to https://247marketnews.com/kblb-disclosure/ for disclaimer information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (KBLB, KTTA, RAVA, WAI, IVVD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.